Trials / Active Not Recruiting
Active Not RecruitingNCT05879744
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Cullinan Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLN-978 | CD19xCD3 T cell engager |
Timeline
- Start date
- 2023-05-31
- Primary completion
- 2026-11-01
- Completion
- 2027-04-01
- First posted
- 2023-05-30
- Last updated
- 2024-05-02
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05879744. Inclusion in this directory is not an endorsement.